Logo

Bioarray PGS+PGD Single Biopsy Kit

Jun 28, 2017

Bioarray has launched its PGS+PGD Single Biopsy kit which screens aneuploidies and identifies embryos with pathological mutation from a single biopsy sample. The kit uses next-generation sequencing technology and bioinformatics analysis to determine whether an embryo carries aneuploidies, such as trisomy of chromosome 21, and allow for users to reject embryos affected by the mutation and/or select those not affected. Users can expect results to be processed within three to five days.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.